While TRAIL and Olaparib used as individual agents exerted minor effects on neurosphere formation, the combination of the two drugs significantly impaired the formation of neurospheres (Fig. 1E–F), suggesting that this combination treatment may affect the glioma stem cell-like fraction. The gene discussed is TNFSF10; the disease is glioma.